secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001193125-25-133730
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics enters up to $500M loan facility with Oxford Finance; $75M initial draw
--------------------------------------------------------------------------------

- Initial $75M funded June 4, 2025; remaining $50M from $125M first tranche drawable in 2026.
- Additional tranches: up to $175M upon milestones, plus $200M uncommitted subject to mutual agreement.
- Interest rate: greater of 1-Month Term SOFR + 4.95% and 8.70%; maturity June 2030 or 2031.
- Collateral on substantially all assets except IP; financial covenants require minimum liquidity or loan coverage ratios.
- Facility fee 0.75% of funded amount; final payment and prepayment fees apply.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312525133730/0001193125-25-133730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312525133730/d869940d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-133730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer